Integrating Diversity, Equity, and Inclusion Approaches into Treatment of Commercial Tobacco Use for Optimal Cancer Care Delivery

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Tobacco-related cancer incidence and mortality and commercial tobacco use have decreased steadily in recent decades, but improvements have not been equitably experienced across population subgroups. A complex interaction across socioecological domains of individual, interpersonal, community/organization, and societal/policy factors influence disparities in tobacco use, treatment, and related health outcomes. NCI's Cancer Center Cessation Initiative (C3I) provides an ideal platform to examine and intervene on multilevel influences across the cancer control continuum to reduce any disproportionate tobacco-related burden and eliminate tobacco-related disparities. The C3I Diversity, Equity, and Inclusion (DEI) Working Group encourages cancer centers to develop, evaluate, and adopt evidence-based practices regarding DEI for prevention and treatment of commercial tobacco use across the cancer control continuum. This paper highlights how 3 C3I sites intervene to address socioecological influences on tobacco use among racially, ethnically, socioeconomically, and geographically diverse patient subgroups. It then outlines ways in which DEI considerations could be integrated into research with patients with cancer who use tobacco and practices related to standards of cancer care. Incorporating DEI considerations in the pursuit of optimal tobacco treatment could facilitate elimination of inequities in population-level cancer outcomes, spanning the full continuum of cancer care from prevention to survivorship.

Original languageEnglish
Pages (from-to)S4-S7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume19
DOIs
StatePublished - Nov 2021

Bibliographical note

Publisher Copyright:
© JNCCN-Journal of the National Comprehensive Cancer Network 2021

Funding

Funding: This supplement was funded by the C3I Coordinating Center contract from the National Cancer Institute (CRDF Award #66590). In addition, authors received funding for their C3I participation via a supplement to their NCI P30 cancer center support grant during the period 2017–2021.

FundersFunder number
National Childhood Cancer Registry – National Cancer Institute
Citrus Research and Development Foundation66590

    ASJC Scopus subject areas

    • Oncology

    Fingerprint

    Dive into the research topics of 'Integrating Diversity, Equity, and Inclusion Approaches into Treatment of Commercial Tobacco Use for Optimal Cancer Care Delivery'. Together they form a unique fingerprint.

    Cite this